S&P 500   4,234.92 (-1.14%)
DOW   33,773.07 (-0.66%)
QQQ   322.52 (-2.05%)
AAPL   171.96 (-1.26%)
MSFT   285.98 (-1.44%)
META   167.83 (-3.91%)
GOOGL   117.00 (-2.64%)
AMZN   138.20 (-2.88%)
TSLA   883.13 (-2.80%)
NVDA   178.09 (-5.14%)
NIO   19.06 (-4.27%)
BABA   89.44 (-1.43%)
AMD   94.82 (-5.60%)
T   18.42 (-0.05%)
MU   60.49 (-3.95%)
CGC   3.79 (-0.52%)
F   15.82 (-2.04%)
GE   77.56 (-2.08%)
DIS   120.15 (-2.05%)
AMC   17.90 (-7.21%)
PYPL   96.79 (-3.07%)
PFE   49.32 (+1.52%)
NFLX   237.95 (-2.94%)
S&P 500   4,234.92 (-1.14%)
DOW   33,773.07 (-0.66%)
QQQ   322.52 (-2.05%)
AAPL   171.96 (-1.26%)
MSFT   285.98 (-1.44%)
META   167.83 (-3.91%)
GOOGL   117.00 (-2.64%)
AMZN   138.20 (-2.88%)
TSLA   883.13 (-2.80%)
NVDA   178.09 (-5.14%)
NIO   19.06 (-4.27%)
BABA   89.44 (-1.43%)
AMD   94.82 (-5.60%)
T   18.42 (-0.05%)
MU   60.49 (-3.95%)
CGC   3.79 (-0.52%)
F   15.82 (-2.04%)
GE   77.56 (-2.08%)
DIS   120.15 (-2.05%)
AMC   17.90 (-7.21%)
PYPL   96.79 (-3.07%)
PFE   49.32 (+1.52%)
NFLX   237.95 (-2.94%)
S&P 500   4,234.92 (-1.14%)
DOW   33,773.07 (-0.66%)
QQQ   322.52 (-2.05%)
AAPL   171.96 (-1.26%)
MSFT   285.98 (-1.44%)
META   167.83 (-3.91%)
GOOGL   117.00 (-2.64%)
AMZN   138.20 (-2.88%)
TSLA   883.13 (-2.80%)
NVDA   178.09 (-5.14%)
NIO   19.06 (-4.27%)
BABA   89.44 (-1.43%)
AMD   94.82 (-5.60%)
T   18.42 (-0.05%)
MU   60.49 (-3.95%)
CGC   3.79 (-0.52%)
F   15.82 (-2.04%)
GE   77.56 (-2.08%)
DIS   120.15 (-2.05%)
AMC   17.90 (-7.21%)
PYPL   96.79 (-3.07%)
PFE   49.32 (+1.52%)
NFLX   237.95 (-2.94%)
S&P 500   4,234.92 (-1.14%)
DOW   33,773.07 (-0.66%)
QQQ   322.52 (-2.05%)
AAPL   171.96 (-1.26%)
MSFT   285.98 (-1.44%)
META   167.83 (-3.91%)
GOOGL   117.00 (-2.64%)
AMZN   138.20 (-2.88%)
TSLA   883.13 (-2.80%)
NVDA   178.09 (-5.14%)
NIO   19.06 (-4.27%)
BABA   89.44 (-1.43%)
AMD   94.82 (-5.60%)
T   18.42 (-0.05%)
MU   60.49 (-3.95%)
CGC   3.79 (-0.52%)
F   15.82 (-2.04%)
GE   77.56 (-2.08%)
DIS   120.15 (-2.05%)
AMC   17.90 (-7.21%)
PYPL   96.79 (-3.07%)
PFE   49.32 (+1.52%)
NFLX   237.95 (-2.94%)
TSE:BLU

BELLUS Health - BLU Stock Forecast, Price & News

C$14.48
-0.18 (-1.23%)
(As of 08/19/2022 01:41 PM ET)
Add
Compare
Today's Range
C$14.38
C$14.62
50-Day Range
C$9.95
C$15.46
52-Week Range
C$3.79
C$16.24
Volume
27,877 shs
Average Volume
125,378 shs
Market Capitalization
C$1.82 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$15.75
BLU stock logo

About BELLUS Health (TSE:BLU) Stock

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.

BELLUS Health Trading Down 0.9 %

BELLUS Health stock traded down C$0.14 during midday trading on Thursday, hitting C$14.61. The company has a quick ratio of 14.75, a current ratio of 15.33 and a debt-to-equity ratio of 0.30. BELLUS Health has a twelve month low of C$3.79 and a twelve month high of C$16.24. The company has a fifty day moving average price of C$12.51 and a 200 day moving average price of C$10.46. The stock has a market capitalization of C$1.84 billion and a P/E ratio of -13.96.

Analysts Set New Price Targets

Separately, HC Wainwright restated a "buy" rating and issued a C$16.00 price target on shares of BELLUS Health in a report on Tuesday, July 12th.

Receive BLU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter.

BLU Stock News Headlines

BELLUS Health (BLU) Investor Presentation - Slideshow
Bellus: Q4 Earnings Snapshot
BELLUS Health Inc. Common Shares (BLU)
Bellus Health (BLU) Reports Q3 Loss
See More Headlines
Receive BLU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter.

BLU Company Calendar

Today
8/19/2022
Next Earnings (Estimated)
11/09/2022

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
C$15.75
High Stock Price Forecast
C$18.00
Low Stock Price Forecast
C$14.00
Forecasted Upside/Downside
+8.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$16,000.00
Price / Sales
113,842.67
Cash Flow
C$2.12 per share
Book Value
C$2.62 per share

Miscellaneous

Free Float
N/A
Market Cap
C$1.82 billion
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Roberto Francesco Bellini (Age 42)
    Pres, CEO & Director
    Comp: $353.03k
  • Mr. Ramzi Benamar (Age 49)
    Chief Financial Officer
    Comp: $607.33k
  • Dr. Denis Garceau (Age 65)
    Chief Scientific Officer
    Comp: $431.87k
  • Mr. Tony Matzouranis (Age 49)
    Sr. VP of Bus. Devel.
    Comp: $272.89k
  • Dr. Catherine M. Bonuccelli M.D. (Age 64)
    Chief Medical Officer
    Comp: $703.77k
  • Dr. Andreas Orfanos FFPM (Age 63)
    M.B.B.Ch, MBA, Chief Operating Officer
  • Mr. Daniel Matthews
    Director of Investor Relations & Communications
  • Mr. Francois Desjardins C.A. (Age 59)
    CPA, CPA, CA, Sr. VP of Fin.
  • Mr. Sebastien Roy (Age 46)
    Corp. Sec.













BLU Stock - Frequently Asked Questions

Should I buy or sell BELLUS Health stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BELLUS Health in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BLU shares.
View BLU analyst ratings
or view top-rated stocks.

What is BELLUS Health's stock price forecast for 2022?

4 brokerages have issued twelve-month target prices for BELLUS Health's stock. Their BLU share price forecasts range from C$14.00 to C$18.00. On average, they expect the company's stock price to reach C$15.75 in the next twelve months. This suggests a possible upside of 9.1% from the stock's current price.
View analysts price targets for BLU
or view top-rated stocks among Wall Street analysts.

How have BLU shares performed in 2022?

BELLUS Health's stock was trading at C$10.17 at the beginning of the year. Since then, BLU shares have increased by 42.0% and is now trading at C$14.44.
View the best growth stocks for 2022 here
.

When is BELLUS Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our BLU earnings forecast
.

What other stocks do shareholders of BELLUS Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BELLUS Health investors own include Exxon Mobil (XOM), Bombardier (BDRBF), AbbVie (ABBV), Energy Transfer (ET), General Electric (GE), Coca-Cola (KO), Alexion Pharmaceuticals (ALXN), Advanced Micro Devices (AMD), Boeing (BA) and Walt Disney (DIS).

What is BELLUS Health's stock symbol?

BELLUS Health trades on the Toronto Stock Exchange (TSX) under the ticker symbol "BLU."

How do I buy shares of BELLUS Health?

Shares of BLU stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is BELLUS Health's stock price today?

One share of BLU stock can currently be purchased for approximately C$14.44.

How much money does BELLUS Health make?

BELLUS Health (TSE:BLU) has a market capitalization of C$1.82 billion and generates C$16,000.00 in revenue each year.

How can I contact BELLUS Health?

BELLUS Health's mailing address is 9-275 Armand-Frappier Blvd, LAVAL, QC H7V 4A7, Canada. The official website for the company is www.bellushealth.com. The company can be reached via phone at +1-450-6804500.

This page (TSE:BLU) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.